title: Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group.
abstract: Acute exacerbations, most of which are due to lower respiratory tract infections, cause great morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD) and most of these are due to lower respiratory tract infections. The aim of this study was to determine the causative organism and the effects of azithromycin, ampicillin sulbactam (sultamicillin), ciprofloxacin and cefaclor monohydrate therapy in COPD. One hundred and six patients with COPD in acute exacerbation were randomized into four groups for empiric antibiotic treatment following lung function tests and sputum examination. The most common strains isolated from sputum were Haemophilus influenzae (30.8%), Streptoccocus pneumoniae (12%) and Moraxella catarrhalis (7.7%). Azithromycin, sultamicillin, ciprofloxacin and cefaclor monohydrate were found to be effective in treating COPD exacerbations.
authors.affiliation: Istanbul University Cerrahpasa School of Medicine, Dept. of Pulmonology, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Umut
authors.forename: B
authors.initials: B
authors.lastname: Tutluoglu
authors.forename: G
authors.initials: G
authors.lastname: Aydin Tosun
authors.forename: B
authors.initials: B
authors.lastname: Müsellim
authors.forename: M
authors.initials: M
authors.lastname: Erk
authors.forename: N
authors.initials: N
authors.lastname: Yildirim
authors.forename: H
authors.initials: H
authors.lastname: Vahapoglu
authors.forename: N
authors.initials: N
authors.lastname: Yilmaz
authors.forename: O
authors.initials: O
authors.lastname: Arseven
authors.forename: H
authors.initials: H
authors.lastname: Türker
authors.forename: M
authors.initials: M
authors.lastname: Erelel
authors.forename: A
authors.initials: A
authors.lastname: Ilvan
authors.forename: V
authors.initials: V
authors.lastname: Göylüsün
authors.forename: T
authors.initials: T
authors.lastname: Yilmaz Kuyucu
authors.forename: F
authors.initials: F
authors.lastname: Koşar
authors.forename: F
authors.initials: F
authors.lastname: Soysal
authors.forename: A
authors.initials: A
authors.lastname: Gür
authors.forename: S
authors.initials: S
authors.lastname: Unutmaz
authors.forename: S
authors.initials: S
authors.lastname: Oztürk
authors.forename: M
authors.initials: M
authors.lastname: Akman
mesh_terms: D000667:Ampicillin / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D002433:Cefaclor / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D013407:Sulbactam / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin; C035444:sultamicillin; D002433:Cefaclor; D000667:Ampicillin; D017963:Azithromycin; D013407:Sulbactam